Description
|
Therapeutic indications: |
To be used only for the radiolabelling of medicinal products, which have been specifically developed and authorised for radiolabelling with this radionuclide. Radiopharmaceutical precursor – Not intended for direct use in patients. |
Qualitative and quantitative compositions: |
Each vial contains 0.925–37 GBq Yttrium (90Y) on the reference date and time (corresponding to 46–1840 nanograms of Yttrium [90Y]) in a volume 0.010–2 mL as Yttrium [90Y] chloride in a diluted hydrochloric acid. |
Pharmaceutical form: |
Radiopharmaceutical precursor, solution. Clear, colourless solution. |
List of excipients: |
Hydrochloric acid (concentrated) |
Posology and method of administration: |
Posology The quantity of ItraPol required for radiolabelling and the quantity of Yttrium (90Y)- labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled. Method of administration ItraPol is intended for in vitro labelling of medicinal products which are subsequently administered by the approved route. |
Shelf life: |
7 days from the date of manufacture. |
Special precautions for storage: |
Store below 25°C, in the original package. |
Nature and content of container: |
Colourless type I glass vial of 2 mL volume closed with a rubber stopper and aluminium seal, placed in a shielding lead container. Pack size: 1 vial During storage, due to ionizing radiation, the vial may change color into yellow- brown. This discoloration has no influence into the product quality. |
For detailed information about this product please refer to the Summary of Product Characteristics or Information for the Patient.
Check our production and delivery schedule: